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MOBILE HEALTH TECHNOLOGY APPLICATIONS ON ATRIAL 
FIBRILLATION 
KAYLYNN JINWEI CONANT 
ABSTRACT 
Atrial fibrillation (AF) is the most common arrhythmia and affects over 
5 million Americans today. Many AF related strokes occur without AF 
being diagnosed prior and often would be preventable with treatment 
such as anticoagulants. Since many cases of AF are paroxysmal in 
nature, they often go unseen during medical visits. However, with 
today’s advancing technology there are several mobile health 
(mhealth) devices that can be used in a home setting to screen or 
monitor a person’s heart rhythm. With so many different types of 
devices being put onto the market, it is important to measure their 
accuracy and feasibility to best understand the readings given by the 
devices. The following devices, Kardia Mobile by AliveCor, 
MyDiagnostick, Zio® Patch by iRhythm Technologies, Inc., and the 
Apple Watch, have been reviewed assessing their accuracy and, based 
on study availability, the overall patients’ experiences with the 
devices. The Kardia Mobile device had mixed results in accuracy, but 
favorable results when it came to participants’ experience when using 
the device. Its biggest drawback in ability to capture asymptomatic or 
 vii 
paroxysmal AF, which is also applicable to the MyDiagnostick, is that it 
does not have constant monitoring. This may result in missing the 
aforementioned types of AF. The MyDiagnostick had consistently high 
specificity and sensitivity results and is very simple in design making it 
easy to use. The Zio® Patch did not have any studies comparing it 
directly to a gold standard 12-lead ECG, but was found by one study to 
be better at detecting AF compared to a 24-hour Holter monitor. It 
was also found to be user-friendly. The Apple Heart Study posed a 
good example of a very large enrollment reaching thousands and 
showed the algorithm to have a 0.84 positive predictive value, but did 
not provide any information on the algorithm’s sensitivity or specificity 
in detecting AF. Its biggest potential stems from the wide use of Apple 
products making it accessible as well as its constant background 
monitoring. Overall, all of the devices have promising features, and 
many have promising results, but should be further studied with 
emphasis on comparing the algorithms to 12-lead ECG standards and 
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Atrial fibrillation (AF) is the most prevalent arrhythmia affecting more 
than 5 million Americans and is projected afflict over 12 million by 
2050 (Benjamin et al., 2017; Miyasaka et al., 2006). Researchers 
estimate that 37% of adults over the age of 55 suffer from AF (Weng 
et al., 2018). Even with the current cohort studies estimating the 
prevalence, due to paroxysmal cases it is estimated that millions go 
undiagnosed and are not included in the estimates (Turakhia et al., 
2018). The disease is characterized as an irregular beating of the 
upper chambers in the heart causing less than optimal flow of blood 
throughout the body (Centers for Disease Control and Prevention, 
n.d.). Due to the decrease in blood flow from the heart, AF has been 
shown to cause increased risk of various damaging and lethal 
conditions including ischemic stroke, heart failure, and sudden cardiac 
death (Odutayo et al., 2016). There is a 5-fold increase in risk for 
stroke, and 1 in 5 of the AF-related strokes occur without AF being 
diagnosed prior to the stroke (Bjorck et al., 2013; Borowsky et al., 
2017). Oral anticoagulants can reduce the relative risk of stroke by 
49% to 74% in patients with AF (Hart et al., 2007). A more timely 
diagnosis of AF could signal the need for appropriate treatment that 
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could benefit the patient to prevent an AF-related stroke. Lam et al. 
(2017) distinguishes a relative timeline indicating when subclinical AF 
cases may originate in their relation to when they become clinically 
diagnosed highlighting the increasing thromboembolic risk and atrial 
cardiomyopathy and the importance of screening (Figure 1). 
 
 
Figure 1. Atrial Fibrillation over Time and its Risks. This figure 
visualizes how episodes of atrial contractions evolve over time from less 
frequent and premature contractions to permanent full-on atrial fibrillation 
episodes with the associated risk for thromboembolisms and cardiomyopathy 
development respectively. PACs stands for premature atrial contractions. 
Based on the individual, the diagnosis may occur earlier or later along the 
time axis (Lam et al., 2017). 
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The main screening techniques used for AF are through variations of 
electrocardiogram (ECG) readings or heart rate monitoring dependent 
on the age group and other present comorbidities (Lam et al., 2017). 
However, due to the nature of paroxysmal atrial fibrillation, diagnosis 
of subclinical cases would be difficult to identify if solely dependent on 
diagnosing in a clinical setting using the golden standard of a 12-lead 
ECG. This would require the patient to be experiencing an AF episode 
in the moment of the clinical visit while having their ECG taken. A 
much sounder way to screen in order to lessen undiagnosed AF cases 
would be to have continuous monitoring or a device that is quickly 
accessible to monitor any episodes or chance opportunities. This could 
result in an earlier AF diagnosis and subsequent implementation of 
treatment, such as oral anticoagulants, that could prevent other 
dangerous health implications such as stroke. 
 
With today’s technological advancements, ECG readings and rhythm 
monitoring are now possible through devices that can be used at home 
and are noninvasive which makes screening and diagnosing easier and 
more accessible. These new technologies include devices that are a 
part of the digital health technology subcategory known as mobile 
health (mHealth). The World Health Organization (2011) defines 
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mHealth as, “medical and public health practice supported by mobile 
devices, such as mobile phones, patient monitoring devices, personal 
digital assistants (PDAs), and other wireless devices” (p. 6). Now a 
person can monitor their heart rhythm and take ECG readings by using 
their mobile device, smartwatch, or another small device that can be 
kept in the comfort of their home. 
 
There are three main categories of mHealth devices: mobile 
applications, wrist-worn wearables, and other handheld measuring 
devices with the latter two requiring the captured information to be 
transmitted to a mobile application or other computing system for 
further interpretation (Giebel & Gissel, 2019). These types of 
technologies are useful replacements for more invasive devices that 
must be implanted through surgery and allow for easy access to ECG 
recordings and cardiac rhythm readings. However, since these are 
newer technologies there have not been many comparative studies 
done to test their efficacy and usability. This literature review will go 
over the following four mHealth technologies being used to detect AF 
in users: KardiaMobile by AliveCor, MyDiagnostick, Zio® Patch by 
iRhythm Technologies, Inc., and the Apple Watch. Studies evaluating 
their efficacies in detecting atrial fibrillation will be reviewed in order to 
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help care providers and patients be more aware of the technology that 
is readily available and its reliability, alongside limited reviews on the 
devices’ usability. A bulk of the publicly available studies from recent 




KardiaMobile by AliveCor 
KardiaMobile by AliveCor is a handheld, single-lead electrode ECG 
device. It requires placing two fingers from each hand on the 
electrodes (Figure 2), and transmits the ECG to almost any iOS or 
Android compatible smartphone or tablet. This device is FDA-cleared 
and a little bigger than the average USB drive (8.2 cm x 3.2 cm x 0.35 
cm). It uses a machine-learning algorithm to detect multiple different 
arrhythmias including AF. The algorithm classifies ECGs into one of the 
four following categories: normal sinus rhythm, possible AF, 




Figure 2. Kardia Mobile by AliveCor. This image exemplifies the general 
positioning for using the Kardia Mobile device and what the interface of the 
application looks like while actively taking an ECG recording. Permission was 
granted to use the images of the Kardia Mobile device from the AliveCor 
website by AliveCor. (AliveCor, n.d.) 
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Multiple studies have been done to assess the accuracy of the 
algorithm in detecting AF as well as the quality of the ECG record 
taken by the device. In terms of the ECG quality collected by the 
Kardia Mobile device, Koltowski et al. (2019) studied 100 patients in 
an academic cardiology care center and recorded with a 12-lead ECG 
and Kardia Mobile device that were later analyzed by three teams of 
cardiologists. It was found that the quality of the ECG records taken by 
the Kardia Mobile device was comparable to a 12-lead ECG, commonly 
referred to as the gold standard for ECG recording (Koltowski et al., 
2019). 
 
However, there have been conflicting results in assessing the accuracy 
of the algorithm to detect AF. Desteghe et al. (2017) studied patients 
in a cardiac ward and geriatric ward, and compared a Kardia Mobile 
recording to a 12-lead ECG or 6-lead ECG recording that was taken 
immediately before the Kardia Mobile one. There were 320 patients in 
the cardiology ward where the 12-lead ECG was used and 125 patients 
in the geriatric ward where the 6-lead ECG was used. The cardiac ward 
arm had 320 subjects with an average age of 67.9 ± 14.6 and 35.6% 
with a known AF diagnosis. The measurements resulted in a 36.8% 
sensitivity, 96.1% specificity, 56% PPV, and 91.9% NPV. However, 
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when the subjects with pacemakers and implantable cardioverter 
defibrillators were removed (n = 265), the sensitivity, specificity, PPV, 
and NPV all went up (54.5%, 97.5%, 66.7%, and 96.0%, 
respectively). In the geriatric ward arm, the average age was 83.3 ± 
5.8, 36% had a known AF diagnosis, and 37.6% were male. The 
results for sensitivity, specificity, PPV, and NPV for the group that 
included subjects with pacemakers and implantable cardioverter 
defibrillators (n = 125) were 72.7%, 98.1%, 88.9%, and 94.4% 
respectfully, and without the subjects with pacemakers and 
implantable cardioverter defibrillators (n = 113) were 78.9%, 97.9%, 
88.2%, and 95.8%, respectfully (Desteghe et al., 2017). 
 
Another study also found that the algorithm should not be used alone 
to detect AF when compared to medical professionals in interpreting 
the ECG records. In a study by Selder et al. (2019), 233 participants 
were given a Kardia Mobile device to use at their home and take 
recordings whenever symptoms were felt. The average age was 58.4 
± 14 with 52% male and 55% diagnosed with atrial fibrillation or atrial 
flutter prior to the trial. There were no limits to the number of ECGs 
they could record. The collected ECGs from the Kardia Mobile device 
were interpreted by specialists. These interpretations were used as the 
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reference group in comparison to the algorithm’s detection capabilities. 
It was found that 20% of the ECGs deemed as possible AF cases by 
the algorithm were diagnosed as non-AF cases by the interpreters. The 
sensitivity, specificity, PPV, and NPV were 92%, 95%, 80%, and 98%, 
respectively, with a team of interpreters used as the reference 
standard. They found that almost 8% of cases diagnosed with AF by 
the interpreters were classified as unclassified or normal rhythm by 
the Kardia Mobile device which they concluded the need to manually 
assess the ECGs in conjunction with the device (Selder et al., 2019). 
 
In contrast, Halcox et al. (2017) showed significantly more AF cases 
were identified using the Kardia Mobile device and diagnosing 
algorithm compared to patients undergoing routine care which 
comprised of regular visits and interactions with their general 
practitioner. The study’s population for both study arms had an 
average age of 72.6 ± 5.4 and required the subjects to not have a 
prior AF diagnosis. For the study arm that required monitoring using 
the Kardia Mobile device, 19 subjects were diagnosed in the yearlong 
study period of the 500 subjects compared to 5 of the 501who were 
diagnosed with AF in the routine care arm where the Kardia Mobile 
device was not used (Halcox et al., 2017).  
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Two studies, Koltowski et al. (2019) and Lowres et al. (2014), found 
the algorithm to have high specificity (100% and 91.4%, respectively) 
and sensitivity (92.8% and 98.5%, respectively) in detecting AF when 
compared to physician interpreted 12-lead ECG recordings. The 
Koltowski et al. (2019) study had 99 Kardia Mobile subjects with an 
average age of 68 ± 14.2, 66% male, and 34 were previously 
diagnosed with AF, whereas the Lowres et al. (2014) study included 
1000 subjects, 44% male, and 104 of the participants had a history of 
AF. William et al. (2018) found the Kardia Mobile algorithm to have 
96.6% sensitivity and 94.1% specificity in comparison with physician 
interpreted ECGs collected by the device. This study include 52 
subjects who had a prior history diagnosis of paroxysmal or persistent 
AF, average age of 68, and 67% male (William et al., 2018). Yan et al. 
(2020) studied a pool of 294 patients who were hospitalized for stroke 
or transient ischemia attack and without a history of AF were 
simultaneous monitored by a Holter monitor and used Kardia Mobile. It 
was found that the Kardia Mobile device had a significantly greater 
detection rate of AF (8.5% of subjects) and detected AF earlier 
(median time of 3 days) than the Holter monitor (2.8% of subjects and 
median time of 8 days) (Yan et al., 2020). 
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Alongside these results, one study collected survey information 
regarding the satisfaction of the experience with the device. Halcox et 
al. (2017) surveyed their subjects measuring their experience with the 
Kardia Mobile device (Figure 3). They invited all 1004 participants to 
take the survey. When asked their preference on whether the subjects 
would want to switch study arms (i.e. from routine care arm to the 
Kardia Mobile arm or vice versa) on a 1-10 visual analog scale, there 
was a much greater preference by the routine care arm to switch to 
the Kardia Mobile arm (mean score, 1.9 versus 6.2; P<0.0001). An 
overwhelming majority responded “extremely or very satisfied” when 
asked about their overall satisfaction, “not at all anxious or slightly 
anxious” when asked about their anxiety regarding the hearth rhythm, 
“not at all restricted” when asked if they felt the usage restricted their 
lifestyle, and “extremely comfortable or very comfortable” when asked 
about their acceptance for sharing the taken information. When asked 
about their confidence in the device, a majority answered “extremely 




Figure 3. Survey Results Measuring User Experience with the Kardia 
Mobile Device. All of these questions were measured on a 5-point Likert 
scale used to assess user experience with the Kardia Mobile device. 
Overwhelming positive results were found when asked about user’s 
satisfaction, anxiety while using the device, any restrictions in lifestyle while 
using the device, confidence in the device’s capabilities, and acceptance of 
sharing the monitored information with the study team (Halcox et al., 2017). 
 
Overall, it appears the actual ability for the Kardia Mobile device to 
take ECG recordings is adequate and the usability based on people’s 
experience with the device has high approval. However, the actual 
 13 
accuracy of the algorithm used to detect AF seems to have mixed 
results and should not be used as a definitive diagnosing tool. 
 
MyDiagnostick 
MyDiagnostick is similar to KardiaMobile in that it is a handheld device 
that measures single-lead ECGs with two electrodes. The device is a 
rod shape that requires the user to grip both sides of the rod as if they 
were holding a T bar in front of them (Figure 4). There are no buttons 
and the device automatically begins to record once held correctly. 
 
 
Figure 4. MyDiagnostick. The two electrodes are the outer segments of the 
bar and are where each hand must be clasped around for proper ECG 
recording. The dots in the middle light up while measurements are taken with 
an ending green or red light based on whether AF is detected or not. 




The device takes one minute to record the ECG and will either flash a 
green light indicating normal cardiac rhythm or a red light indicating 
AF. The algorithm is set to diagnose AF once the arrhythmia is present 
for 75% of the measuring time (45 seconds). The device will hold 140 
ECGs, prioritizes the more recent AF recordings, and will override non-
AF ECGs once the 140 ECG limit is hit. All of these features makes the 
device user friendly and prepared for long-term autonomous use. The 
MyDiagnostick can connect to any computer or laptop with a USB 





Figure 5. Examples of ECG Tracings Collected by the MyDiagnostick. 
The left image is an example of a normal sinus rhythm tracing and the left 
one is an example of an AF tracing (Tieleman et al., 2014). 
  
Multiple studies have been done to test the accuracy of the algorithm 
as well as the quality of the single-lead ECG recorded by the device. 
Zwart et al. (2020), Vaes et al. (2014), and Tieleman et al. (2014) all 
tested the accuracy of the device’s algorithm compared to a 12-lead 
ECG golden standard. In both the Tieleman et al. (2014) and Vaes et 
al. (2014) studies, a 12-lead ECG was taken immediately after the 
MyDiagnostick recordings were administered in an outpatient 
cardiology clinic and primary care setting, respectively. The Tieleman 
et al. (2014) study found the MyDiagnostick to have 100% sensitivity 
and 95.9% specificity, and similarly the Vaes et al. (2014) study 
concluded the device to have 94% sensitivity and 93% specificity. The 
Tieleman et al. (2014) study included 192 subjects with an average 
age of 69 ± 12.6 and 48.4% were male. The specificity increased to 
97% when tested in the subgroup made up of ≥65 years (Tieleman et 
al., 2014). The Vaes et al. (2014) study had 181 subjects with an 
average age of 74.6 ± 9.7 and 52% male. A sample was selected with 
a goal to have at least a 50% prevalence of AF diagnosed prior to the 
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study. A sample of 161 subjects with a history of AF diagnosis and 30 
without were studied and 10 were excluded due to active pacemakers 
at the time of the study. During the time of the study there was a 54% 
prevalence of AF, and using their measurements a 45% PPV and 99% 
NPV was estimated for an age ≥65 years population with a 6% AF 
prevalence (Vaes et al., 2014). 
 
The Zwart et al. (2020) study differed from the other two studies in 
multiple ways and was set in a geriatric outpatient clinic, memory 
clinic, and Fall or Syncope day clinic. Instead of testing the patients 
once with the MyDiagnostick, the patients were tested in consecutive 
visits. The 12-lead ECG was only measured for the baseline recording 
and following any AF cases detected by the MyDiagnostick. The study 
population was made up of 439 subjects with an average age of 78 ± 
7, 46% men, and 25.7% (n = 113) had a diagnosis history of AF. In 
the conclusion of the study, the MyDiagnostick was found to have 90% 
sensitivity, 99% specificity, 73.5% PPV, and 99.7% NPV (Zwart et al., 
2020). 
 
Two studies reviewed the quality of the ECGs measured by the 
MyDiagnostick device. In both studies, two cardiologists reviewed the 
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ECGs rating them on a qualitative scale. In the Battipaglia et al. 
(2016) study, the two interpreters agreed on 82% of the 50 ECGs 
analyzed. In the Zwart et al. (2020) study, 1344 single-lead ECGs 
were analyzed and a discussion was held if the two cardiologists were 
in disagreement. The final ratings included 1111 (85.9%) good, 160 
(12.4%) acceptable, and 23 (1.8%) as poor and the remaining 50 
were discarded due to artifacts or unreliable atrial activity assessment. 
 
In another study, instead of measuring the quality of ECG recordings 
on a qualitative scale, two arrhythmia specialists rated 855 single-lead 
ECGs on varying amounts of unwanted noise. The raters included two 
arrhythmia specialists who discussed any discrepancies between the 
two to come up with a consensus rating (Figure 6). Instead of 60 
second recordings, this study did 15 second recordings. The study 
resulted in 240 (28%), 446 (52%), 107 (13%), and 62 (7%) rated as 
NS 1, NS 2, NS 3, and NS 4, respectively, with the higher numerical 




Figure 6. Examples of ECG Tracings with Noise Scores. The tracings 
taken by the MyDiagnostick were rated based on a consensus between two 
arrhythmia specialists. The ECGs were rated on a scale of 1-4 with 4 having 
the most noise and 1 the least. The more noise present, the harder it is to 
read and interpret the recorded ECG (Battipaglia et al., 2016). 
 
Zio® Patch by iRhythm Technologies, Inc. 
The Zio® patch by iRhythm Technologies, Inc. is a single-use, non-
invasive, adhesive patch that records a continuous single-lead ECG for 
up to 14 days (Figure 7). It is waterproof and has a button that may 
be activated once symptoms occur to time stamp the event on the 
continuously recorded data. This device is FDA-cleared and can be 
applied to the user in a clinical setting or at home. The device stores 
its readings and once the wear time is completed, the user may send 
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the patch back to the facility (iRhythm Technologies, Inc.) to be 
analyzed and a report is then sent to the ordering care provider. 
 
 
Figure 7. Zio® patch by iRhythm Technologies, Inc. The Zio® patch is 
worn on the chest for up to 14 days of monitoring. It can be applied by a 
clinician or by the user in any setting. It is waterproof and can be worn while 
sleeping, exercising, or even showering (iRhythm Technologies, Inc., n.d.). 
 
The greatest benefit of a device like the Zio® patch is its prolonged 
period of monitoring in comparison to a 12-lead ECG or 24-hour Holter 
monitor that may miss a significant number of patients with 
paroxysmal AF (Jabaudon et al., 2004). Continuous ECG monitoring in 
an inpatient setting for approximately 3 days may have significantly 
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higher sensitivity in detecting paroxysmal AF than a 24-hour Holter, 
but it is not sufficient for those in an outpatient setting (Rizos et al., 
2012). Other devices that allow for monitoring over three days such as 
loop recorders or implanted monitors are cumbersome and require 
invasive procedures (Gladstone et al., 2014; Sanna et al., 2014). For 
these reasons, the Zio® patch poses as a device that could provide 
prolonged monitoring for those not in an inpatient setting, is easy and 
comfortable to use, and can potentially provide significant detection of 
paroxysmal AF. 
 
This device is used in several studies, but only one compares its 
accuracy to a pacemaker during the entirety of the patch’s wear time. 
Other studies compare its detection to a 24-hour Holter monitor 
(Barrett et al., 2014; Eysenck et al., 2019; Kaura et al, 2019; 
Rosenberg et al., 2013). The device is being included due to its high 
prevalence in the literature and clinical settings even though there 
does not appear to be any studies solely comparing its efficacy to 
another device that is used for the same time period. The uniqueness 
of this device is that it is a non-invasive device that can monitor for up 
to 14 days. 
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In the Eysenck et al. (2019) study, the Zio® patch and three other 
devices, Novascor’s R.TEST 4 (RT), Nuubo’s ECG vest, and the 
Carnation Ambulatory Monitor, were worn in conjunction with a dual 
chamber permanent pacemaker (PPM) with the main purpose of 
comparing Novascor RT with the other three devices. There were 21 
subjects who each had a PPM and a history of AF. The study had them 
cycle through wearing the four devices in random order for 14 days 
with at least seven days in between each change of external monitor. 
The Zio® Patch was found to have comparable measurements of AF 
burden with the PPM (0.99 R squared, 0.24 mean squared error) and 
was significantly better at estimating the AF burden in comparison with 
the RT. The Zio® patch was also found to be 12.3 times more accurate 
than the RT (p = 0.02). Other results of the same study found that 
there was no significant difference in satisfaction between the Zio® 
Patch and RT, the Zio® patch had significantly longer wear time than 
RT, and the time expenditure when using for the Zio® patch was lower 
than that of RT (Eysenck et al., 2019). 
 
The other three studies reviewed for the Zio® patch compared its 
detection capabilities to a 24-hour 3-lead Holter monitor. In the first of 
the three, Kaura et al. (2019) monitored patients who had an ischemic 
 22 
stroke or transient ischemic attack for paroxysmal AF detection. The 
study resulted in usable data from 47 patients using the Holter 
monitor and 43 using a Zio® patch. The recruited subjects were 
required to have no history of AF, were 61.1% male, and had an 
average age of 70.4 ± 13.2 years. The ones who were in the Zio® 
patch arm also wore a Holter monitor. The Zio® patch was found 
superior to the Holter monitor with 16.3% of the subjects (n = 7) had 
paroxysmal AF events detected compared to the 2.1% found by the 
Holter monitor (n = 1). For those who wore both the Zio® patch and 
Holter monitor, the Holter monitor detected paroxysmal AF in 4.7% (n 
= 2) compared to the 16.3% (n = 7) found by the Zio® Patch (Kaura 
et al., 2019). 
 
In Barrett et al. (2014), 146 patients wore the Zio® patch and Holter 
simultaneously and measured the events recorded by both as well as 
collected survey responses from the patients and providers on their 
experience with the different technologies. There were 146 patients 
studied with a median age of 64 years and 41.8% were male. All of 
the study subjects were under evaluation for cardiac arrhythmia. 
During the entirety of the time, the Zio® patch found significantly 
more events than the Holter monitor with or without the 
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supraventricular tachycardias which were considered less clinically 
important (96, 61 and 41, 27 respectively). During the 24 hours where 
both devices were in use, the Holter monitor detected significantly 
more events, and  without the supraventricular tachycardias the Holter 
detected more but not significantly more (61, 52 and 27, 24 
respectively). At the end of the study, 93.7% (n = 134) of the patients 
found the Zio® patch to be comfortable compared to 76.2% (n = 109) 
who found the Holter to be comfortable. There were 51.7% (n = 74) of 
participants who found the Holter monitor affected their daily lives 
whereas only 10.5% (n = 15) agreed in sentiment while using the 
Zio® patch. Overall, 81% (n = 111) favored the Zio® Patch. Of the 
ordering physicians, 90% (n = 92) thought the Zio® patch achieved a 
definitive diagnosis whereas 64% (n = 64) said the same for the 
Holter monitor (Barrett et al., 2014). 
 
The final study reviewed studied the patterns of AF in AF patients who 
were undergoing AF management by simultaneously wearing a Zio® 
patch and Holter monitor to test responses to therapies and to 
diagnose any other arrhythmias. Seventy-four subjects were 
monitored with an average age of 64.5 ± 8.1, 54.7% were male, and 
67.1% had previous signs of AF. In the first 24 hours all 25 episodes 
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of AF were detected by the Holter monitor and Zio® patch with 
comparable AF burden recordings. There were no significant 
differences in detection between those with and without symptoms. It 
was found that the Zio® patch detected AF episodes in more patients 
than the Holter monitor as a result of the longer monitoring period (n 
= 18) and the clinical classification of the AF pattern changed in 21 
patients during the longer wear time of the Zio® patch (Table 1) 
(Rosenberg et al., 2013). 
 
    
Zio® Patch 
  








 None 32 17 0 49 
Holter Paroxysmal 0 12 0 12 
 Persistent 0 4 5 9 
 Total 32 33 5 70 
Table 1. Change in Clinical Classification of AF Due to Zio® Patch 




The accuracy of using the Apple Watch to detect atrial fibrillation has 
been tested in a recent study utilizing its photoplethysmography (PPG) 
technology and a detection algorithm (Perez et al., 2019). This study 
is being included due to the prevalence of Apple users. Apple continues 
to dominate the smartwatch market holding 51.4% of the sales and 
shipping around 42 million smartwatches during just the first half of 
2020 (Lamkin, n.d.). Also equipped in the Apple Watch Series 4 and 
later versions is an ambulatory single-lead ECG recording feature. 
 
The Apple Health Study is the largest remote study of its kind thus far 
with over 400,000 patients enrolled (Perez et al., 2019). The large 
enrollment can be credited with the inherent nature of the study being 
fully remote and the fact that the device used in the study is already 
widely used. In order to be eligible for the study, the devices need to 
be an iPhone 5s or later and an Apple Watch Series 1 or later 
(Turakhia et al., 2019). 
 
Turakhia et al. (2019) goes over the thorough description of methods 
used for the study. Once enrolled, if participants have an initial 
tachogram with irregularity that meets the criteria, the algorithm will 
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be triggered. Once the algorithm has been triggered, opportunistic 
tachograms will be taken to evaluate for more PPG irregularities. Once 
four subsequent irregular tachograms are measured, a notification is 
sent to the participant. The requirement for multiple irregularities is to 
increase the accuracy. Those who receive the notification are required 
to go through a telehealth visit where eligibility is confirmed (Table 2). 
They are then sent an ambulatory ECG patch that is used as a 
reference to compare with the measurements taken by the Apple 
Watch. A second study visit is conducted as well as two different 
surveys were given out; a 90-day survey to those who received a 














 1. iPhone (5 s or later) with iOS version 11.0 or later 
 2. Apple Watch (Series 1 or later) with watchOS version 4.0 or later 
 3. Age ≥22 years at time of eligibility screening 
 4. US resident (50 states or D.C.) 
 5. Proficient in written and spoken English, defined by self-report 
 6. Valid phone number associated with iPhone, ascertained from self-report. 
 7. Valid email address, ascertained from self-report. 
Exclusion criteria 
 1. Self-reported diagnosis or history of Atrial Fibrillation at the time of consent. 
 2. Self-reported diagnosis or history of Atrial Flutter at the time of consent. 
 3. Currently on anticoagulation therapy, as self-reported at the time of consent. 
_____________________________________________________________ 
Table 2. Inclusion and Exclusion Criteria for the Apple Heart Study. 
Taken from (Turakhia et al., 2019). 
 
In the Perez et al. (2019) study, all of the results from the various 
endpoints were presented and analyzed. Of the 417,136 people who 
were enrolled, 2161 received notifications of irregular pulse rates. Of 
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those 2161 participants, only 945 participated in the initial telehealth 
visit, and 658 of the 945 were found to be eligible for the next step 
where they were shipped an ambulatory ECG. There were 450 who 
returned the ECG monitors. Of the monitor returning participants, 86 
were found to have irregular pulse notifications from their Apple Watch 
while simultaneously being monitored by the ambulatory ECG. Of the 
86 participants, 72 of them were found to have AF on the 
simultaneously recorded ECGs (Figure 8). This resulted in a 0.84 
positive predictive value for those who were notified and were 




Figure 8. Participant Selection for the Apple Heart Study. Of the initial 
419,297 participants included in the study population, 2,161 received the 
irregular pulse notifications. In the end, there were 72 participants who 
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followed all of the subsequent steps of the trial and were found to have AF 
detected on the ECG monitor while simultaneously triggering an irregular 
pulse notification on the Apple Watch. AF denotes atrial fibrillation and ECG 
electrocardiography (Perez et al., 2019). 
 
Apple has also released a new feature for its Apple Watches Series 4 
and later: the ability to take single-lead ECG recordings. One electrode 
is found on the digital crown and the other on the back of the watch. 
The feature has been granted De Novo classification by the FDA. This 
feature is user-triggered and includes an algorithm that classifies ECGs 
as either sinus rhythm, AF, or inconclusive. The study included 602 
subjects who recorded single-lead ECGs using the Apple Watch and 
ECG app while simultaneously recording a 12-lead ECG by researchers 
(Using Apple Watch for Arrhythmia Detection, 2018). The study was 
found to have greater than 98% sensitivity and greater than 99% 








Kardia Mobile by AliveCor 
So far, many of the studies out there have varying results for the 
accuracy and usefulness of the Kardia Mobile device and algorithm 
used to detect cardiovascular incidents such as AF. Only one appears 
to delve into the whether the actual ECG record collected is 
comparable to a 12-lead ECG standard (Koltowski et al., 2019). Even 
though the algorithm itself seems to be of greater interest in a 
majority of the studies, the technology behind the single-lead ECG of 
the Kardia Mobile device should be better researched to build a 
stronger understanding and foundation when measuring the device’s 
effectiveness. An interesting finding was that electrode solution spray 
significantly increased the quality of the ECG records from the Kardia 
Mobile device which could be further studied when looking further into 
the device’s ECG quality (Desteghe et al., 2017). 
 
A few of the studies reviewed used reference groups that have a lot of 
potential for discrepancies in the results. The study that intended to 
measure AF detection in subjects that have yet to be diagnosed with 
AF at the time of enrollment compared a group using the Kardia Mobile 
technology with a group undergoing their usual routine care (Halcox et 
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al., 2017). There were no guidelines as to what the routine care 
included other than a subject continuing their regular visits with their 
general practitioner which could result in great variability affecting the 
results of this study. Most of the studies used reference groups that 
included a small group of electrophysiologists and other cardiology 
professionals to interpret the ECGs resulting in a potential bias in 
interpretations due to the limited number of interpreters (Desteghe et 
al., 2017; Koltowski et al., 2019; Selder et al., 2019; William et al., 
2018). Though human bias may be inherent to the type of study, the 
bias may be lessened by increasing the randomization in interpreters 
or increasing the number of interpreters interpreting each ECG and 
normalizing the results. 
 
Another contributor to varying results may be due to how the study 
groups were selected. For instance, one study that showed a low 
positive predictive value (PPV) indicated that it was likely due to the 
low prevalence of AF in the study group. This study also had a 
selection bias being that the patients enrolled were based on 
physicians’ discretion (Selder et al., 2019). It should be recognized 
that study populations with a higher prevalence of AF are expected to 
have higher PPV. Since AF prevalence increases with age, it can be 
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expected that study populations with an older population would be 
expected to have a higher PPV (Labombarda et al., 2017). Therefore, 
it makes sense that the Selder et al. (2019) study had a lower PPV 
than some of the other studies. The average age was 58.4 ± 14 in the 
Selder et al. (2019) study, whereas the other studies reviewed had 
average ages that were at least 10 years greater. Thus, for screening 
purposes in the general population compared to populations specific to 
older patients or those with a higher prevalence of AF, as seen in a 
majority of the studies reviewed, the PPV would be much lower. This is 
apparent in the Desteghe et al. (2017) study where the cardiac ward 
arm (average age of 67.9 ± 14.6) had a much lower PPV than the 
geriatric ward arm (average age of 83.3 ± 5.8) in detecting AF. It 
must be acknowledged that these accuracy measurements are skewed 
due to the populations that were studied where AF prevalence is much 
higher than in the general population. 
 
Furthermore, multiple of the studies, including those that did and did 
not find the technology accurate, had small sample sizes (≤ 1000 
subjects) and were single center studies (Desteghe et al., 2017; 
Koltowski et al., 2019; Lowres et al., 2014; Selder et al., 2019; 
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William et al., 2018; Yan et al., 2020). More studies should be 
conducted to include greater numbers and a wider range of subjects. 
 
A drawback of this device is that is it does not allow for continuous 
monitoring. The Kardia Mobile device can be useful for monitoring by 
taking regular measurements. It might also be accessible when 
symptoms appear to be increasing thus triggering one to record an 
ECG. However, if the AF is asymptomatic then there is no trigger that 
pushes the person to take an ECG measurement that could have led 
up to a diagnosis. 
 
AlivCore has also recently released a 6-lead ECG mhealth device. Not 
many studies have been done to study this device’s accuracy, but the 
increased leads poses a potential for increased accuracy. More studies 
should be done on this device with an emphasis on its accuracy 
comparing the single-lead device and a 12-lead ECG standard. 
 
MyDiagnostick 
Based on the study results, the MyDiagnostick appears to be a good 
screening device for AF with multiple results of a high specificity and 
sensitivity (Tieleman et al., 2014; Vaes et al., 2014; Zwart et al., 
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2020). Without extra buttons to push in order to use the device, the 
use of the red or green light indicators make the device simple and 
easy to use. The 60 second recording also makes it a short step that 
could easily be added to routine visits for AF screening such as during 
routine visits with a primary care provider (Rivezzi et al., 2020). More 
studies like the Kassenbrood et al. (2016) study should be done to 
assess the accuracy of other recording time periods and compare the 
varying amounts to the 60 second recordings to assess any loss in 
quality. This could potentially find as accurate a reading in a shorter 
time frame allowing for even more patients to be screened in the same 
amount of time as well as other savings in resources and providers’ 
time. 
 
Furthermore, if the device is used for screening, multiple tests would 
be beneficial in diagnosing additional new AF cases such as those done 
in the Zwart et al. (2020) study. Since each patient had repeated 
screening, more new AF cases were found compared to studies that 
only used one screening (Kaasenbrood et al., 2016; Tieleman et al., 
2014; Zwart et al., 2020). This could be due to many of the cases 
being paroxysmal so the opportunistic testing caught more of these 
cases during an active AF episode. It also shows that there is a high 
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risk for undetected AF if not repetitively screened. For this study 
however, there was not standardization in the number of visits each 
patient did or in the interval between each visit, the patients simply 
had to go to consecutive visits in order to qualify (Zwart et al., 2020). 
To get a better idea of the ideal spacing and optimal amount of 
screening to capture as the most amount of AF cases, more studies 
should be done while also taking into consideration the cost-
effectiveness of such spaced out screenings. 
 
All of the studies that evaluated the quality of the single-lead ECGs 
taken by the MyDiagnostick device used two interpreters (Battipaglia 
et al., 2016; Kaasenbrood et al., 2016; Zwart et al., 2020). The 
discrepancies in quality ratings in the Battipaglia et al. (2016) study, 
where the two interpreters disagreed on the ratings in 18% of the 
ECGs), shows that there is a large margin for personal bias and 
differences in intepretation in this type of analysis. More studies should 
be done with more interpreters to get a more standardized conclusion 
of the ECGs collected by the device. 
 
Even though high specificity and sensitivity in detecting AF by the 
MyDiagnostick were found, the lack of 100% sensitivity means that 
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there is potential for false positive results. A false positive result would 
mean the MyDiagnostick indicating AF is detected when in fact there is 
no AF. Because of this, rather than taking the device’s detection 
analysis as fact, a red light result on the MyDiagnostick could instead 
point to patients that would need further monitoring and testing to 
verify AF such Holter monitoring or a 12-lead ECG recording. Both of 
these extra steps take much more time and resources than the 
MyDiagnostick, suggesting that preliminary screening by this device 
could save time and money for both the healthcare provider and 
patient. 
 
Overall, the MyDiagnosticks seems promising in its ability to be used 
as a first line screening device of AF. The easy-to-use design makes it 
ideal for at home solutions as well as quick use in clinics for the 
potential to be routinely used in outpatient settings where populations 
are at high risk for AF. More studies should be used in finding the 
optimal usage of the device when screening as well as further studies 
assessing the quality of the ECGs. Even without the algorithm, if 
shorter time-period ECGs taken by the device could be deemed 
accurate enough to use in diagnosing, the use of the device has the 
potential in saving time and expenses. 
 38 
 
Zio® Patch by iRhythm Technologies, Inc. 
Since there are limited studies that test the Zio® patch’s accuracy to 
other reference monitors, it is recommended that further 
investigations and comparisons need to be conducted. In the Kaura et 
al. (2019) study, the Zio® patch was found to be more accurate than 
the RT, but less accurate than a pacemaker which is considered the 
gold standard. More studies should be done in comparison to a 
pacemaker gold standard that can also be measured for a prolonged 
period of time to assess the device’s accuracy in detection. Also, since 
the four different devices being compared were worn at different 
times, it is possible that there were varying numbers of incidents per 
the time periods with each device. The pacemakers used also varied in 
brand and further studies should keep this in mind. The diagnostic 
yield has been compared in the three studies indicated above, but the 
overall accuracy compared to the 24-hour Holter monitor’s accuracy is 
still unclear (Barrett et al., 2014; Kaura et al., 2019; Rosenberg et al., 




An issue with the Kaura et al. (2019) study was its very low retention 
rate with an about 20% dropout rate almost entirely due to the Holter 
monitor where the compliance for the extended monitoring is low. All 
four studies reviewed for the Zio® patch had low numbers of 
participants and should be further replicated with a larger subject pool 
(Barrett et al., 2014; Eysenck et al., 2019; Kaura et al., 2019; 
Rosenberg et al., 2013). Furthermore, the studies should include more 
real-life applications to better predict the patch’s usability outside of a 
study environment. For instance, the Barrett et al. (2014) highlighted 
that the application of the patch by researchers could affect the 
predictive power of the study when applied to patients using the patch 
at home. 
 
Overall, in comparison to the 24-hour Holter monitor and RT, the Zio® 
patch has been found to be better at detecting events, including AF, 
and significantly better at detecting AF burden with a majority reason 
due to the longer monitoring period (Barrett et al., 2014; Eysenck et 
al., 2019; Kaura et al., 2019; Rosenberg et al., 2013). Though the 
Zio® patch was not compared directly to the PPM, the evidence for 
being significantly more accurate than the RT and comparable 
agreement of AF burden to the PPM (0.99 R squared, 0.24 mean 
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squared error) is promising and should be studied further (Eysenck et 
al., 2019;). In the Eysenck et al. (2019) study, all subjects had a 
history of AF and had a PPM. There were 21 subjects, but the PPMs 
varied amongst them which could have resulted in biases (Eysenck et 
al., 2019). The iRhythm Technologies, Inc. provides reports that are 
overlooked by professionals, but the accuracy of the algorithm used 
should also be assessed. The Barrett et al. (2014) study pointed out 
two of the events that were detected by the Holter monitor and not 
the Zio® patch were due to algorithm misclassification and seven due 
to a processing error of the iRhythm Technologies, Inc. physician 
reviewer indicating there may be discrepancies missed in other studies 
due to similar errors. 
 
The first seven days have been found to be ample time for arrhythmia 
detection with 96.6% of the arrhythmias detected by the seventh day 
using a Zio® patch (Turakhia et al., 2013). For the studies that 
measured wear time of the Zio® patch, all were worn for over seven 
days with mean of 10.8 days in the Rosenberg et al. (2013) study, 
median 11.1 days in the Barrett et al. (2014) study, and mean 11.825 
days in the Kaura et al. (2019) study. This indicates that even though 
the patch was not worn for the full 14 -day period, the shorter wear 
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times of the device in real-life applications appear to be adequate as 
the majority of the detections were found during the studies which still 
gave optimal results. 
 
The results from the Barrett et al. (2014) study about patients’ 
experiences with the device in comparison to the 24-hour Holter 
monitor, give a promising review of overall satisfaction when using the 
device. Inherent to the product, there may be doubts that the delay 
between wearing the monitor and receiving results from the iRhythm 
Technologies, Inc. However, the Rosenberg et al. (2013) study found 
that even without real-time detection that all patients were referred to 
appropriate management if needed, but the study was limited in size 
and further studies should be done to assess. 
 
Both the results for the satisfaction with the device and benefits of 
having a device that monitors for a longer period of time supports the 
Zio® patch as being a user-friendly device that may detect more 




The Apple Health Study never had the goal of being used as a 
screening tool or to provide definitive diagnoses of AF. Instead, the 
hope was to have a high positive predictive power which was achieved 
with the 84% of participants who received a notification and also 
showed AF on the simultaneous ECG recording (Perez et al., 2019). 
The data was ultimately skewed towards a younger population which 
could have affected the results rather than being targeted toward 
those at a higher risk for AF (i.e. ≥ 65 years old). Though the 
enrollment was large, the follow-up was very poor which resulted in a 
small fraction of the population left that actually received and returned 
the patch making the population likely biased. A younger population 
would have less AF prevalence than an older one potentially lowering 
the PPV. Furthermore, to support the initial goals of the study, the goal 
was to have at least 503 ambulatory ECG recorded individuals per age 
group (Turakhia et al., 2019). These numbers were not reached, but 
further assessment of the study procedure could be analyzed to 
improve strategies for higher retention. The retention rates themselves 
can be used in future studies to give researchers a better idea when 
setting up large-scale remote studies. It should also be recognized that 
the lack of AF recording while using the ambulatory ECG device could 
be due to the nature of paroxysmal AF. During early stages of AF it is 
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more likely to be paroxysmal in nature. Since the data was skewed 
towards a younger population where AF is not common or more likely 
to be paroxysmal if present, it is possible that more AF cases were 
missed during the limited monitoring period. 
 
Furthermore, since all of the measurements were taken in the 
subjects’ free-living environments rather than a controlled 
environment where more variables can be controlled, the data is 
bound to have more unwanted noise. Almost anyone could potentially 
meet the eligibility requirements; and the environments where 
measurements were taken were random and situational. This means 
there are no controlling factors that can be replicated to the test 
metrics. The study also did not assess real performance characteristics 
of the algorithm. There is no sensitivity or specificity measurements 
for the algorithm itself and more of this should be evaluated. 
 
A couple more smartwatches that should be further studied for efficacy 
and accuracy are the Samsung Galaxy Watch3 and Galaxy Active2. 
Both of these devices now have an FDA-cleared ECG monitoring app 
and are comparable in their utility to the Apple watches. 
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With further studies and innovation, a device with the ability to both 
passively monitor pulse accurately detecting irregularities and record 
accurate ECGs could be groundbreaking for screening and monitoring 
purposes. The current technology is not quite ready to be able to be 
used for screening or diagnosing, but has promising potential with 
further innovation. Though, the 84% of notifications correlating with 
evidenced AF on an ECG and high specificity and sensitivity of the ECG 
algorithm in AF detection, these devices could be used at the very 
least to increase awareness and for individuals to seek out further 
healthcare. With smartwatches and like technology, the potential for 
large-scale studies done remotely provide the opportunity for more 
widespread studies that could be applicable to large masses like the 




After careful analysis of the literature, there appears to be much 
promise in the capabilities of the various mhealth devices to be able to 
detect and monitor for AF, but there is a long way to go. Though some 
studies used a gold standard to compare the device to, many lacked 
this indisputable comparison standard. Many more studies need to be 
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done to further assess their efficacies with stable reference groups and 
results must be interpreted with the study population demographics in 
mind to address any biases. Further investigation into their cost-
effectiveness should be evaluated when applying the studies into real 
life situations where the devices will either be used to screen or as a 
routine monitoring device. Accessibility for all ages seems to have 
been taken into account in the making of these technologies, and 
should not be ignored in further development as the majority of those 
who could benefit are older and less technology prone. If the 
technology in commonly owned products, such as smartwatches, can 
be sophisticated and developed enough to be reliable, a constant 
background monitoring could open up the potential to address a 
majority of the missed paroxysmal AF cases. Thus, helping both 
consumers and healthcare professionals combat the unwanted effects 









Barrett, P. M., Komatireddy, R., Haaser, S., Topol, S., Sheard, J., Encinas, J., 
Fought, A. J., & Topol, E. J. (2014). Comparison of 24-hour Holter 
Monitoring with 14-day Novel Adhesive Patch Electrocardiographic 
Monitoring. The American Journal of Medicine, 127(1). 
https://doi.org/10.1016/j.amjmed.2013.10.003 
Battipaglia, I., Gilbert, K., Hogarth, A. J., & Tayebjee, M. H. (2016). Screening 
For Atrial Fibrillation In The Community Using A Novel ECG Recorder. 
Journal of Atrial Fibrillation, 9(2). https://doi.org/10.4022/jafib.1433 
Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R., 
de Ferranti, S. D., Floyd, J., Fornage, M., Gillespie, C., Isasi, C. R., 
Jimenez, M. C., Jordan, L. C., Judd, S. E., Lackland, D., Lichtman, J. H., 
Lisabeth, L., Liu, S., Longenecker, C. T., Mackey, R. H., Matsushita, K., 
Mozaffaria, D., Mussolino, M. E., Nasir, K., Neumar, R. W., Palaniappan, 
L., Pandey, D. K., Thiagarajan, R. R., Reeves, M. J., Ritchey, M., 
Rodriguez, C. J., Roth, G. A., Rosamond, W. D., Sasson, C., Towfighi, A., 
Tsao, C. W., Turner, M. B., Virani, S. S., Voeks, J. H., Willey, J. Z., 
Wilkins, J. T., Wu, J. H. Y., Alger, H. M. Wong, S. S., and Muntner, P. 
(2017). Heart Disease and Stroke Statistics–2017 Update: A Report From 
the American Heart Association. Circulation, 135(10). 
doi/10.1161/CIR.0000000000000485 
 47 
Björck Staffan, Palaszewski Bo, Friberg Leif, & Bergfeldt Lennart. (2013). Atrial 
Fibrillation, Stroke Risk, and Warfarin Therapy Revisited. Stroke, 44(11), 
3103–3108. https://doi.org/10.1161/STROKEAHA.113.002329 
Borowsky, L. H., Regan, S., Chang, Y., Ayres, A., Greenberg, S. M., & Singer, D. 
E. (2017). First Diagnosis of  Atrial Fibrillation at the Time of Stroke. 
Cerebrovascular Diseases (Basel, Switzerland), 43(3–4), 192–199. 
 https://doi.org/10.1159/000457809 
CDC. (2020, September 8). Atrial Fibrillation | cdc.gov. Centers for Disease 
Control and Prevention. 
https://www.cdc.gov/heartdisease/atrial_fibrillation.htm 
Desteghe, L., Raymaekers, Z., Lutin, M., Vijgen, J., Dilling-Boer, D., Koopman, 
P., Schurmans, J., Vanduynhoven, P., Dendale, P., & Heidbuchel, H. 
(2017). Performance of handheld electrocardiogram devices to detect 
atrial fibrillation in a cardiology and geriatric ward setting. Europace: 
European Pacing, Arrhythmias, and Cardiac Electrophysiology: Journal of 
the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular 
Electrophysiology of the European Society of Cardiology, 19(1), 29–39. 
https://doi.org/10.1093/europace/euw025 
Eysenck, W., Freemantle, N., & Sulke, N. (2020). A randomized trial evaluating 
the accuracy of AF detection by four external ambulatory ECG monitors 
compared to permanent pacemaker AF detection. Journal of Interventional 
 48 
Cardiac Electrophysiology, 57(3), 361–369. 
https://doi.org/10.1007/s10840-019-00515-0 
Giebel, Godwin Denk, & Gissel, C. (2019). Accuracy of mHealth Devices for 
Atrial Fibrillation Screening: Systematic Review. JMIR MHealth and 
UHealth, 7(6), e13641. https://doi.org/10.2196/13641 
Gladstone, D. J., Spring, M., Dorian, P., Panzov, V., Thorpe, K. E., Hall, J., Vaid, 
H., O’Donnell, M., Laupacis, A., Côté, R., Sharma, M., Blakely, J. A., 
Shuaib, A., Hachinski, V., Coutts, S. B., Sahlas, D. J., Teal, P., Yip, S., 
Spence, J. D., … Mamdani, M. (2014, June 25). Atrial Fibrillation in 
Patients with Cryptogenic Stroke (world) [Research-article]. 
Http://Dx.Doi.Org/10.1056/NEJMoa1311376; Massachusetts Medical 
Society. https://doi.org/10.1056/NEJMoa1311376 
Halcox Julian P.J., Wareham Kathie, Cardew Antonia, Gilmore Mark, Barry 
James P., Phillips Ceri, & Gravenor Michael B. (2017). Assessment of 
Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to 
Screen for Atrial Fibrillation. Circulation, 136(19), 1784–1794. 
https://doi.org/10.1161/CIRCULATIONAHA.117.030583 
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007). Meta-analysis: Antithrombotic 
Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial 
Fibrillation. Annals of Internal Medicine, 146(12), 857–867. 
https://doi.org/10.7326/0003-4819-146-12-200706190-00007 
 49 
Jabaudon, D., Sztajzel, J., Sievert, K., Landis, T., & Sztajzel, R. (2004). 
Usefulness of ambulatory 7-day ECG monitoring for the detection of atrial 
fibrillation and flutter after acute stroke and transient ischemic attack. 
Stroke, 35(7), 1647–1651. 
https://doi.org/10.1161/01.STR.0000131269.69502.d9 
Kaasenbrood, F., Hollander, M., Rutten, F. H., Gerhards, L. J., Hoes, A. W., & 
Tieleman, R. G. (2016). Yield of screening for atrial fibrillation in primary 
care with a hand-held, single-lead electrocardiogram device during 
influenza vaccination. Europace, 18(10), 1514–1520. 
https://doi.org/10.1093/europace/euv426 
KardiaMobile. (n.d.-a). AliveCor, Inc. Retrieved January 19, 2021, from 
https://store.alivecor.com/products/kardiamobile 
Kaura, A., Sztriha, L., Chan, F. K., Aeron-Thomas, J., Gall, N., Piechowski-
Jozwiak, B., & Teo, J. T. (2019). Early prolonged ambulatory cardiac 
monitoring in stroke (EPACS): An open-label randomised controlled trial. 
European Journal of Medical Research, 24. 
https://doi.org/10.1186/s40001-019-0383-8 
Koltowski, L., Balsam, P., Glłowczynska, R., Rokicki, J. K., Peller, M., Maksym, 
J., Blicharz, L., Maciejewski, K., Niedziela, M., Opolski, G., & Grabowski, 
M. (2019). Kardia Mobile applicability in clinical practice: A comparison of 
Kardia Mobile and standard 12-lead electrocardiogram records in 100 
 50 
consecutive patients of a tertiary cardiovascular care center. Cardiology 
Journal, 0(0), Article 0. https://doi.org/10.5603/CJ.a2019.0001 
Labombarda, F., Hamilton, R., Shohoudi, A., Aboulhosn, J., Broberg, C. S., 
Chaix, M. A., Cohen, S., Cook, S., Dore, A., Fernandes, S. M., Fournier, 
A., Kay, J., Macle, L., Mondésert, B., Mongeon, F.-P., Opotowsky, A. R., 
Proietti, A., Rivard, L., Ting, J., … Khairy, P. (2017). Increasing 
Prevalence of Atrial Fibrillation and Permanent Atrial Arrhythmias in 
Congenital Heart Disease. Journal of the American College of Cardiology, 
70(7), 857–865. https://doi.org/10.1016/j.jacc.2017.06.034 
Lam, A., Goulouti, E., & Roten, L. (2017). The search for atrial fibrillation and its 
impact on public health. Swiss Medical Weekly, 147(2526). 
https://doi.org/10.4414/smw.2017.14447 
Lamkin, P. (n.d.). Apple Still Leading The Way With Smartwatch Shipments But 
Huawei Is Hot On Its Heels. Forbes. Retrieved January 26, 2021, from 
https://www.forbes.com/sites/paullamkin/2020/08/26/apple-still-leading-
the-way-with-smartwatch-shipments-but-huawei-is-hot-on-its-heels/ 
Lowres, N., Neubeck, L., Salkeld, G., Krass, I., McLachlan, A. J., Redfern, J., 
Bennett, A. A., Briffa, T., Bauman, A., Martinez, C., Wallenhorst, C., Lau, 
J. K., Brieger, D. B., Sy, R. W., & Freedman, S. B. (2014). Feasibility and 
cost-effectiveness of stroke prevention through community screening for 
 51 
atrial fibrillation using iPhone ECG in pharmacies. Thrombosis and 
Haemostasis, 111(6), 1167–1176. https://doi.org/10.1160/TH14-03-0231 
Miyasaka Yoko, Barnes Marion E., Gersh Bernard J., Cha Stephen S., Bailey 
Kent R., Abhayaratna Walter P., Seward James B., & Tsang Teresa S.M. 
(2006). Secular Trends in Incidence of Atrial Fibrillation in Olmsted 
County, Minnesota, 1980 to 2000, and Implications on the Projections for 
Future Prevalence. Circulation, 114(2), 119–125. 
https://doi.org/10.1161/CIRCULATIONAHA.105.595140 
MyDiagnostick Medical. (n.d.). Retrieved January 30, 2021, from 
https://www.mydiagnostick.com/product.html 
Odutayo, A., Wong, C. X., Hsiao, A. J., Hopewell, S., Altman, D. G., & Emdin, C. 
A. (2016). Atrial fibrillation and risks of cardiovascular disease, renal 
disease, and death: Systematic review and meta-analysis. BMJ, 354, 
i4482. https://doi.org/10.1136/bmj.i4482 
Perez, M. V., Mahaffey, K. W., Hedlin, H., Rumsfeld, J. S., Garcia, A., Ferris, T., 
Balasubramanian, V., Russo, A. M., Rajmane, A., Cheung, L., Hung, G., 
Lee, J., Kowey, P., Talati, N., Nag, D., Gummidipundi, S. E., Beatty, A., 
Hills, M. T., Desai, S., … Turakhia, M. P. (2019). Large-Scale Assessment 
of a Smartwatch to Identify Atrial Fibrillation. New England Journal of 
Medicine. https://doi.org/10.1056/NEJMoa1901183 
 52 
Rivezzi, F., Vio, R., Bilato, C., Pagliani, L., Pasquetto, G., Saccà, S., Verlato, R., 
Migliore, F., Iliceto, S., Bossone, V., & Bertaglia, E. (2020). Screening of 
unknown atrial fibrillation through handheld device in the elderly. Journal 
of Geriatric Cardiology : JGC, 17(8), 495–501. 
https://doi.org/10.11909/j.issn.1671-5411.2020.08.008 
Rizos Timolaos, Güntner Janina, Jenetzky Ekkehart, Marquardt Lars, Reichardt 
Christine, Becker Rüdiger, Reinhardt Roland, Hepp Thomas, Kirchhof 
Paulus, Aleynichenko Elena, Ringleb Peter, Hacke Werner, & Veltkamp 
Roland. (2012). Continuous Stroke Unit Electrocardiographic Monitoring 
Versus 24-Hour Holter Electrocardiography for Detection of Paroxysmal 
Atrial Fibrillation After Stroke. Stroke, 43(10), 2689–2694. 
https://doi.org/10.1161/STROKEAHA.112.654954 
Rosenberg, M. A., Samuel, M., Thosani, A., & Zimetbaum, P. J. (2013). Use of a 
Noninvasive Continuous Monitoring Device in the Management of Atrial 
Fibrillation: A Pilot Study. Pacing and Clinical Electrophysiology, 36(3), 
328–333. https://doi.org/10.1111/pace.12053 
Sanna, T., Diener, H.-C., Passman, R. S., Di Lazzaro, V., Bernstein, R. A., 
Morillo, C. A., Rymer, M. M., Thijs, V., Rogers, T., Beckers, F., Lindborg, 
K., & Brachmann, J. (2014, June 25). Cryptogenic Stroke and Underlying 
Atrial Fibrillation (world) [Research-article]. 
 53 
Http://Dx.Doi.Org/10.1056/NEJMoa1313600; Massachusetts Medical 
Society. https://doi.org/10.1056/NEJMoa1313600 
Selder, J. L., Breukel, L., Blok, S., van Rossum, A. C., Tulevski, I. I., & Allaart, C. 
P. (2019). A mobile one-lead ECG device incorporated in a symptom-
driven remote arrhythmia monitoring program. The first 5,982 Hartwacht 
ECGs. Netherlands Heart Journal, 27(1), 38–45. 
https://doi.org/10.1007/s12471-018-1203-4 
Tieleman, R. G., Plantinga, Y., Rinkes, D., Bartels, G. L., Posma, J. L., Cator, R., 
Hofman, C., & Houben, R. P. (2014). Validation and clinical use of a novel 
diagnostic device for screening of atrial fibrillation. Europace, 16(9), 1291–
1295. https://doi.org/10.1093/europace/euu057 
Turakhia, M. P., Shafrin, J., Bognar, K., Trocio, J., Abdulsattar, Y., Wiederkehr, 
D., & Goldman, D. P. (2018). Estimated prevalence of undiagnosed atrial 
fibrillation in the United States. PLOS ONE, 13(4), e0195088. 
https://doi.org/10.1371/journal.pone.0195088 
Using Apple Watch for Arrhythmia Detection December 2018. (2018). 11. 
Vaes, B., Stalpaert, S., Tavernier, K., Thaels, B., Lapeire, D., Mullens, W., & 
Degryse, J. (2014). The diagnostic accuracy of the MyDiagnostick to 
detect atrial fibrillation in primary care. BMC Family Practice, 15, 113. 
https://doi.org/10.1186/1471-2296-15-113 
 54 
Weng, L.-C., Preis, S. R., Hulme, O. L., Larson, M. G., Choi, S. H., Wang, B., 
Trinquart, L., McManus, D. D., Staerk, L., Lin, H., Lunetta, K. L., Ellinor, P. 
T., Benjamin, E. J., & Lubitz, S. A. (2018). Genetic Predisposition, Clinical 
Risk Factor Burden, and Lifetime Risk of Atrial Fibrillation. Circulation, 
137(10), 1027–1038. 
https://doi.org/10.1161/CIRCULATIONAHA.117.031431 
WHO Global Observatory for eHealth & World Health Organization. (2011). 
MHealth: New horizons for health through mobile technologies. World 
Health Organization. 
http://www.who.int/goe/publications/goe_mhealth_web.pdf 
William, A. D., Kanbour, M., Callahan, T., Bhargava, M., Varma, N., Rickard, J., 
Saliba, W., Wolski, K., Hussein, A., Lindsay, B. D., Wazni, O. M., & 
Tarakji, K. G. (2018). Assessing the accuracy of an automated atrial 
fibrillation detection algorithm using smartphone technology: The iREAD 
Study. Heart Rhythm, 15(10), 1561–1565. 
https://doi.org/10.1016/j.hrthm.2018.06.037 
Yan, B., Tu, H., Lam, C., Swift, C., Ho, M. S., Mok, V. C. T., Sui, Y., Sharpe, D., 
Ghia, D., Jannes, J., Davis, S., Liu, X., & Freedman, B. (2020). Nurse Led 
Smartphone Electrographic Monitoring for Atrial Fibrillation after Ischemic 
Stroke: SPOT-AF. Journal of Stroke, 22(3), 387–395. 
https://doi.org/10.5853/jos.2020.00689 
 55 
Zio Monitoring. (n.d.). Retrieved January 30, 2021, from 
https://www.irhythmtech.com/providers/zio-service/zio-monitors 
Zwart, L. A., Jansen, R. W., Ruiter, J. H., Germans, T., Simsek, S., & Hemels, M. 
E. (2020). Opportunistic screening for atrial fibrillation with a single lead 
device in geriatric patients. Journal of Geriatric Cardiology : JGC, 17(3), 
149–154. https://doi.org/10.11909/j.issn.1671-5411.2020.03.007 
 56 
VITA 
 57 
 58 
 59 
